An 8-Point Device Evaluation Checklist for Post-Merger Medical Technology (NuVasive, Globus Medical, SpO2, Fundus Cameras)

I work in quality and brand compliance for a medical technology company. I review every product implementation checklist before it reaches customers—roughly 200 items a year, and I've been doing this for more than four years. In 2024, I rejected about 9% of first submissions because of labeling or support gaps. Since the Globus Medical–NuVasive merger closed in 2023, I've spent most of that review time checking one thing: whether the combined portfolio still meets the standards we promised.

This isn't a product review. It's the checklist I use when preparing to standardize a new device, whether it's a surgical spine system, a pulse oximeter, or a fundus camera. If you're an OR manager, a supply-chain leader, or a surgeon who gets pulled into device selection, this is exactly the flow I follow. It has eight steps.

Use this checklist when you're selecting a new device after a merger, standardizing a class of devices across multiple locations, or renewing a contract for a surgical system or a monitoring device. If you're just replacing one broken unit with the same model, you don't need all eight steps. Jump to Step 4 and at least confirm the replacement hasn't changed.

1. Start with intended use, not the marketing name

Check the label first. FDA clearance is device-specific. A 510(k) for a legacy NuVasive product doesn't bless every rebranded version of that product after a merger, and it certainly doesn't cover a Globus Medical listing unless the submission was updated. Verify the cleared intended-use statement against how your hospital plans to use it. Do not rely on the sales rep's word.

Before you look at clinical data, ask for the current Instructions for Use and the clearance letter, not just the product brochure. In an integrated portfolio, there's a habit of carrying promotional copy from both companies forward. That copy can be outdated. In one review, we found an old flyer claiming “for anterior approach” while the cleared label only supported a posterior approach. It would have been a mess if a surgeon had used it as intended by the flyer.

• Pulse oximeter: Make sure everyone on the team knows what SpO2 is. SpO2 is peripheral capillary oxygen saturation—an estimate of oxygen saturation measured by pulse oximetry. If the device's label says spot-check only and you want continuous monitoring, that's a mismatch.
• Fundus camera: A camera cleared for anterior-segment photos isn't automatically approved for retinal screening. Check the exact intended-use language before building a screening workflow around it.

Checkpoint: You can point to the exact cleared intended use on the label.

2. Map compatibility before you get seduced by the spec sheet

This is where simplification bites people. It's tempting to think you can compare unit prices and a few performance specs. But identical specs from different vendors can result in wildly different outcomes in your OR. The same is true after a merger: a NuVasive retractor system and a Globus Medical implant line may sit in the same catalog, but that doesn't guarantee their instruments mate with each other or with your navigation platform.

Ask for a written compatibility matrix. Check rails, connectors, table mounts, fluoroscopy integration, EMR interfaces, and software versions. Also check the room: Does the monitor mount fit the boom? Does the camera connect to the hospital network? Is the table adapter for the retractor system actually available? Some part numbers exist in the catalog but have six-month backorders. Ask the vendor to confirm lead times before you standardize.

Checkpoint: You have a written compatibility matrix with all relevant part numbers.

3. Verify clinical services and surgeon training are real

NuVasive built its name partly on clinical services and surgeon education. Those services were a big reason hospitals chose its MIS systems. When Globus Medical acquired NuVasive, the support structure changed. Some teams stayed; some didn't. Don't assume the old NuVasive rep who used to bring cadavers to your lab is still on the route.

Get in writing what training is included—proctoring, cadaver sessions, online modules, OR case coverage. Ask how many trainers are in your state and what the response time is for a 2 a.m. “we're stuck in surgery” call. Ask for names and contact information for the regional clinical support specialist. If a rep says “the support is kinda the same as before,” that's not a plan.

Checkpoint: You know who answers a support call, and how fast.

4. Inspect quality consistency, not just the brochure

Quality isn't a single test result. It's a pattern. Ask suppliers for lot-to-lot records, sterilization validation, packaging performance data, and non-conformance reports. If they hesitate, you've learned something.

In our Q1 2024 quality audit, we received a batch of sterile barriers where the seal wasn't holding under the standard leak test. The vendor said it was “within industry tolerances.” It wasn't within ours. We rejected the lot and added a leak-test clause to every contract. That clause has saved us from two rejected batches since.

Ask for the supplier's corrective and preventive action summary for the last two years. You don't need proprietary details. You need to know whether there are recurring issues. Also ask about packaging testing: drop tests, accelerated aging, seal integrity. These are the details that determine whether a device arrives intact and stays sterile.

Checkpoint: You've seen batch data and rejection history for the specific product you're standardizing.

5. Calculate total cost, including the invisible line items

The first quote for a device might look 18% cheaper than the incumbent. Then you add software licensing, annual service, mandatory training credits, single-use accessories, and shipping. Suddenly it's not cheaper.

One integration took about three weeks—or rather, closer to four after we added the missing validation tests. The delay wasn't because the device failed; it was because the supplier didn't include integration testing in the quote. Always ask: what is not included?

5 minutes of verification beats 5 days of correction.

It's almost a cliché in my department, but it's the reason we make every step visible. Remember to include the cost of downtime. If a system has an annual failure that takes two days to fix, the downtime cost alone may be larger than the service contract. That's a line item most financial models miss.

Checkpoint: You can list every cost line over a three-year horizon.

6. Confirm data integration, cybersecurity, and what the data means

For any device that touches a patient or an EHR, data is part of the product. A pulse oximeter's SpO2 number doesn't exist in a vacuum. Does the device transmit continuously? Does it log trends? Is the waveform stored? Does it connect to your central monitoring station or your EHR via HL7/FHIR? What happens when Wi-Fi drops?

Pulse oximeters are tested for accuracy against a CO-oximeter across a claimed SpO2 range, per ISO 80601-2-61. Check the accuracy table for dark skin pigmentation, low perfusion, and motion. This isn't optional if you're using the device to titrate oxygen or track a post-op patient.

Fundus cameras have the same data problem in a different form. A high-resolution image is useless if the export to PACS fails or the DICOM viewer isn't calibrated. Verify the actual image path, not the brochure's interoperable. Ask to see the cybersecurity documentation: software bill of materials, penetration test summary, and patching policy.

Checkpoint: You know how data flows from device to chart, including failure behavior.

7. Check the product lifecycle roadmap

This is the step most people skip. Portfolio rationalization is inevitable after a merger. Globus Medical and NuVasive both had strong spine portfolios, and after the combined company closed the deal in 2023, it was always going to have to decide which implant systems continued, which were updated, and which were sunset.

I know because I've felt the pain of skipping this step. I knew I should ask about discontinuation plans before choosing the implant, but thought “what are the odds a flagship product gets cut?” Well, the odds caught up with me nine months later. We didn't have a formal lifecycle review process when we standardized on a newly integrated implant. The equipment still worked, but replacement instruments and future components vanished. We had to switch mid-stream. At least, that's been my experience with post-merger portfolios.

Always ask for a written product roadmap. Even if the vendor won't share confidential dates, they can tell you whether a product is strategic or legacy. “We'll continue to support it” without a date is not a roadmap. Another signal: if a price sheet, website, or catalog uses the word legacy or no longer available to new customers, treat that as a sunset warning.

Checkpoint: You have a product roadmap in writing, and a legacy date if there is one.

8. Document your verification—then file it

Every approval should be documented: who checked what, who signed off, which spec sheets were compared, which vendor promises are written down. I tell every team the same thing: a checklist is the cheapest insurance you'll ever buy.

Create a shared folder with the signed checklist, the IFU, the compatibility matrix, the training plan, and the roadmap. Send a copy to the contracting officer before the purchase order goes out. This prevents the “vendor changed the scope after we signed” conversation. If you skip a step, write down why. “Skipped the compatibility check because the vendor said it would work” is a sentence that will haunt you later. At least it haunts me.

Checkpoint: A signed verification record exists for each step.

Common mistakes I still see

• Treating SpO2 as if it's the same as a direct arterial oxygen measurement. It's an estimate. In low perfusion, it can be delayed or inaccurate.
• Trusting verbal promises about merger-related product support. Get them in writing.
• Comparing devices on price per unit instead of cost over the contract life.
• Forgetting that a fundus camera is part of a diagnostic workflow. If the image doesn't reach the reading system intact, the camera hasn't done its job.

In 2023, Globus Medical acquired NuVasive. That combination gives hospitals a broader spine portfolio and a bigger service footprint—but broader doesn't mean simpler. Labels are changing, product lines are being rationalized, and support structures are being reorganized. That's exactly when a checklist earns its keep.